Celecoxib: Considerations regarding its potential disease-modifying properties in osteoarthritis

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Zweers, Manon C ^a   de Boer, Tineke N ^a   van Roon, Joël ^a   Bijlsma, Johannes W J ^a   Lafeber, Floris P J G ^a   Mastbergen, Simon C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACECLOFENAC; ADAMTS1 PROTEIN; AGGRECAN; CELECOXIB; CHONDROITIN SULFATE; COLLAGEN; COLLAGENASE 3; GELATINASE A; GELATINASE B; GLUCOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; OSTEOPROTEGERIN; PLACEBO; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICULAR CARTILAGE; BONE; BONE MATRIX; BONE METABOLISM; BONE PLATE; CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; COST EFFECTIVENESS ANALYSIS; EMBASE; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY CELL; MEDLINE; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; PROTEOGLYCAN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; UNSPECIFIED SIDE EFFECT; ANIMAL; ENZYMOLOGY; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; PATHOLOGY;

ANIMALS; ANTIRHEUMATIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOARTHRITIS; PYRAZOLES; SULFONAMIDES;

EID: 84858843599     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3437     Document Type: Review

References (90)

1. Bijlsma JW, Knahr K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Pract Res Clin Rheumatol 2007, 21:59-76. 10.1016/j.berh.2006.08.013, 17350544.
2. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol 2006, 33:2271-2279.
3. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000, 39(Suppl 2):3-12.
4. Clouet J, Vinatier C, Merceron C, Pot-vaucel M, Maugars Y, Weiss P, Grimandi G, Guicheux J. From osteoarthritis treatments to future regenerative therapies for cartilage. Drug Discov Today 2009, 14:913-925. 10.1016/j.drudis.2009.07.012, 19651235.
5. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000, 43:4-13. 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V, 10643694.
6. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
7. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003, 33:155-167. 10.1016/S0049-0172(03)00134-3, 14671726.
8. Hawkey CJ. COX-2 inhibitors. Lancet 1999, 353:307-314. 10.1016/S0140-6736(98)12154-2, 9929039.
9. Bingham CO. Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve Clin J Med 2002, 69(Suppl 1):SI5-12.
10. Alvarez-Soria MA, Herrero-Beaumont G, Sanchez-Pernaute O, Bellido M, Largo R. Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast--comparison to its effects on osteoarthritic chondrocytes. Rheumatology (Oxford) 2008, 47:627-633.
11. Mastbergen SC, Bijlsma JW, Lafeber FP. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 2005, 13:519-526. 10.1016/j.joca.2005.02.004, 15922186.
12. Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, Sasamata M, Harada S, Akama H, Tazaki H, Chung UI, Takato T, Nakamura K, Kawaguchi H. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. J Bone Miner Res 2006, 21:219-227.
13. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001, 15:2057-2072. 10.1096/fj.01-0390rev, 11641233.
14. Abramson SB, Attur M. Developments in the scientific understanding of osteoarthritis. Arthritis Res Ther 2009, 11:227. 10.1186/ar2655, 2714096, 19519925.
15. Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2000, 2:459-465. 10.1007/s11926-000-0021-y, 11123098.
16. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002, 46:1789-1083. 10.1002/art.10356, 12124863.
17. Attur M, Al-Mussawir HE, Patel J, Kitay A, Dave M, Palmer G, Pillinger MH, Abramson SB. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor. J Immunol 2008, 181:5082-5088.
18. Tchetina EV, Di Battista JA, Zukor DJ, Antoniou J, Poole AR. Prostaglandin PGE2 at very low concentrations suppresses collagen cleavage in cultured human osteoarthritic articular cartilage: this involves a decrease in expression of pro-inflammatory genes, collagenases and COL10A1, a gene linked to chondrocyte hypertrophy. Arthritis Res Ther 2007, 9:R75. 10.1186/ar2273, 2206385, 17683641.
19. Mastbergen SC, Lafeber FP, Bijlsma JW. Selective COX-2 inhibition prevents pro-inflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 2002, 41:801-808.
20. El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 2003, 30:2444-2451.
21. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 2006, 8:R2. 10.1186/ar1846, 1526565, 16356188.
22. Mastbergen SC, Bijlsma JW, Lafeber FP. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 2005, 13:519-526. 10.1016/j.joca.2005.02.004, 15922186.
23. Iimoto S, Watanabe S, Takahashi T, Shimizu A, Yamamoto H. The influence of Celecoxib on matrix synthesis by chondrocytes under mechanical stress in vitro. IntJ Mol Med 2005, 16:1083-1088.
24. Sanchez C, Mateus MM, Defresne MP, Crielaard JM, Reginster JY, Henrotin YE. Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal anti-inflammatory drugs. J Rheumatol 2002, 29:772-782.
25. Nakamura H, Masuko K, Yudoh K, Kato T, Nishioka K. Effects of celecoxib on human chondrocytes--enhanced production of chemokines. Clin Exp Rheumatol 2007, 25:11-16.
26. Jeffrey JE, Aspden RM. Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro. Arthritis Res Ther 2007, 9:R129. 10.1186/ar2346, 2246251, 18096078.
27. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, Stuchin SA, Patel IR, Abramson SB. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997, 99:1231-1237. 10.1172/JCI119280, 507937, 9077531.
28. Mastbergen SC, Bijlsma JW, Lafeber FP. Synthesis and release of human cartilage matrix proteoglycans are differently regulated by nitric oxide and prostaglandin-E2. Ann Rheum Dis 2008, 67:52-58. 10.1136/ard.2006.065946, 17485421.
29. Watanabe Y, Namba A, Honda K, Aida Y, Matsumura H, Shimizu O, Suzuki N, Tanabe N, Maeno M. IL-1beta stimulates the expression of prostaglandin receptor EP4 in human chondrocytes by increasing production of prostaglandin E2. Connect Tissue Res 2009, 50:186-193. 10.1080/03008200802588451, 19444759.
30. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988, 82:2026-2037. 10.1172/JCI113823, 442785, 3264290.
31. Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003, 5:94-103. 165039, 12718749.
32. Tsutsumi R, Ito H, Hiramitsu T, Nishitani K, Akiyoshi M, Kitaori T, Yasuda T, Nakamura T. Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes. Rheumatol Int 2008, 28:727-736. 10.1007/s00296-007-0511-6, 18080123.
33. Pelletier JP, Jovanovic DV, Lascau-Coman V, Fernandes JC, Manning PT, Connor JR, Currie MG, Martel-Pelletier J. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000, 43:1290-1299. 10.1002/1529-0131(200006)43:6<1290::AID-ANR11>3.0.CO;2-R, 10857787.
34. Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol 1995, 146:75-85. 1870754, 7856740.
35. Cao M, Westerhausen-Larson A, Niyibizi C, Kavalkovich K, Georgescu HI, Rizzo CF, Hebda PA, Stefanovic-Racic M, Evans CH. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J 1997, 324(Pt 1):305-310. 1218431, 9164871.
36. Matsuda K, Nakamura S, Matsushita T. Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatol Int 2006, 26:991-995. 10.1007/s00296-006-0107-6, 16437200.
37. Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana J, Egido J, Largo R. Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 2008, 16:1484-1493. 10.1016/j.joca.2008.04.022, 18547825.
38. Schmidt N, Pautz A, Art J, Rauschkolb P, Jung M, Erkel G, Goldring MB, Kleinert H. Transcriptional and post-transcriptional regulation of iNOS expression in human chondrocytes. Biochem Pharmacol 2010, 79:722-732. 10.1016/j.bcp.2009.10.012, 19854161.
39. Wilbrink B, Nietfeld JJ, Den OW, van Roy JL, Bijlsma JW, Huber-Bruning O. Role of TNF alpha, in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage. Br J Rheumatol 1991, 30:265-271. 10.1093/rheumatology/30.4.265, 1863822.
40. Loeuille D, Chary-Valckenaere I, Champigneulle J, Rat AC, Toussaint F, Pinzano-Watrin A, Goebel JC, Mainard D, Blum A, Pourel J, Netter P, Gillet P. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum 2005, 52:3492-3501. 10.1002/art.21373, 16255041.
41. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005, 64:1263-1267. 10.1136/ard.2004.025270, 1755629, 15731292.
42. Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 2010, 62:647-657.
43. Sahap AO. Leukotriene B4 and prostaglandin E2-like activity in synovial fluid in osteoarthritis. Prostaglandins Leukot Essent Fatty Acids 1990, 39:253-254. 10.1016/0952-3278(90)90002-3, 2162064.
44. Alvarez-Soria MA, Largo R, Santillana J, Sanchez-Pernaute O, Calvo E, Hernandez M, Egido J, Herrero-Beaumont G. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006, 65:998-1005. 10.1136/ard.2005.046920, 1798252, 16476713.
45. Berenbaum F. Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol 2004, 16:616-622. 10.1097/01.bor.0000133663.37352.4a, 15314504.
46. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001, 44:585-594. 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.0.CO;2-C, 11263773.
47. Yang SF, Hsieh YS, Lue KH, Chu SC, Chang IC, Lu KH. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. Clin Biochem 2008, 41:109-116. 10.1016/j.clinbiochem.2007.10.011, 17996201.
48. Busso N, Peclat V, So A, Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997, 56:550-557. 10.1136/ard.56.9.550, 1752434, 9370880.
49. Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, Chan ES, Gomez PF, Abramson SB. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 2003, 171:6080-6089.
50. Cha HS, Ahn KS, Jeon CH, Kim J, Koh EM. Inhibitory effect of cyclooxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 2004, 24:207-211.
51. Kusunoki N, Ito T, Sakurai N, Suguro T, Handa H, Kawai S. A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. J Pharmacol Exp Ther 2005, 314:796-803. 10.1124/jpet.105.086116, 15870389.
52. Lev-Ari S, Strier L, Kazanov D, Elkayam O, Lichtenberg D, Caspi D, Arber N. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 2006, 45:171-177.
53. Kusunoki N, Yamazaki R, Kawai S. Pro-apoptotic effect of nonsteroidal anti-inflammatory drugs on synovial fibroblasts. Mod Rheumatol 2008, 18:542-551. 10.1007/s10165-008-0102-8, 18642053.
54. Parada-Turska J, Rzeski W, Majdan M, Kandefer-Szerszen M, Turski WA. Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro. Eur J Pharmacol 2006, 535:95-97. 10.1016/j.ejphar.2006.02.009, 16533508.
55. Audo R, Deschamps V, Hahne M, Combe B, Morel J. Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2007, 9:R128. 10.1186/ar2342, 2246250, 18076767.
56. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98:736-747. 10.1093/jnci/djj206, 16757698.
57. Muraoka T, Hagino H, Okano T, Enokida M, Teshima R. Role of subchondral bone in osteoarthritis development: A comparative study of two strains of guinea pigs with and without spontaneously occurring osteoarthritis. Arthritis Rheum 2007, 56:3366-3374. 10.1002/art.22921, 17907190.
58. Bolbos RI, Zuo J, Banerjee S, Link TM, Ma CB, Li X, Majumdar S. Relationship between trabecular bone structure and articular cartilage morphology and relaxation times in early OA of the knee joint using parallel MRI at 3 T. Osteoarthritis Cartilage 2008, 16:1150-1159. 10.1016/j.joca.2008.02.018, 2580796, 18387828.
59. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, Altman RD, Christiansen C. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 2008, 16:638-646. 10.1016/j.joca.2008.01.014, 18362080.
60. Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T, Takato T, Nakamura K, Kawaguchi H. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J Bone Miner Res 2001, 16:2074-2081. 10.1359/jbmr.2001.16.11.2074, 11697804.
61. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?. Keio J Med 2009, 58:29-40. 10.2302/kjm.58.29, 19398882.
62. Yavropoulou MP, Yovos JG. Osteoclastogenesis--current knowledge and future perspectives. J Musculoskelet Neuronal Interact 2008, 8:204-216.
63. Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Duval N, Martel-Pelletier J. Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone 2008, 43:284-291. 10.1016/j.bone.2008.04.006, 18539107.
64. Igarashi K, Woo JT, Stern PH. Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. Biochem Pharmacol 2002, 63:523-532. 10.1016/S0006-2952(01)00861-9, 11853703.
65. Han SY, Lee NK, Kim KH, Jang IW, Yim M, Kim JH, Lee WJ, Lee SY. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood 2005, 106:1240-1245. 10.1182/blood-2004-12-4975, 15860667.
66. Kawashima M, Fujikawa Y, Itonaga I, Takita C, Tsumura H. The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Mod Rheumatol 2009, 19:192-198. 10.1007/s10165-008-0149-6, 19198759.
67. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004, 47:550-5578. 10.1021/jm030912m, 14736236.
68. Segovia-Silvestre T, Neutzsky-Wulff AV, Sorensen MG, Christiansen C, Bollerslev J, Karsdal MA, Henriksen K. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet 2009, 124:561-577. 10.1007/s00439-008-0583-8, 18987890.
69. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 2001, 44:2768-2776. 10.1002/1529-0131(200112)44:12<2768::AID-ART464>3.0.CO;2-I, 11762937.
70. Kwan TS, Amiable N, Pelletier JP, Boileau C, Lajeunesse D, Duval N, Martel-Pelletier J. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford) 2009, 48:1482-1490.
71. Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis Rheum 2010, 62:478-488. 10.1002/art.27204, 20112374.
72. Watanabe Y, Namba A, Aida Y, Honda K, Tanaka H, Suzuki N, Matsumura H, Maeno M. IL-1beta suppresses the formation of osteoclasts by increasing OPG production via an autocrine mechanism involving celecoxib-related prostaglandins in chondrocytes. Mediators Inflamm 2009, 2009:308596. 2829618, 20204061.
73. Usui M, Xing L, Drissi H, Zuscik M, O'Keefe R, Chen D, Boyce BF. Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res 2008, 23:314-325. 2636701,2636701, 17967138.
74. Masuyama R, Stockmans I, Torrekens S, Van LR, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006, 116:3150-3159. 10.1172/JCI29463, 1635166, 17099775.
75. Breuil V, Schmid-Antomarchi H, Schmid-Alliana A, Rezzonico R, Euller-Ziegler L, Rossi B. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J 2003, 17:1751-1753.
76. Mastbergen SC, Marijnissen AC, Vianen ME, Zoer B, van Roermund PM, Bijlsma JW, Lafeber FP. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatology (Oxford) 2006, 45:405-413.
77. Huh JE, Baek YH, Kim YJ, Lee JD, Choi DY, Park DS. Protective effects of butanol fraction from Betula platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis. J Ethnopharmacol 2009, 123:515-521. 10.1016/j.jep.2008.08.028, 18817862.
78. de Boer TN, Huisman AM, Polak AA, Niehoff AG, van Rinsum AC, Saris D, Bijlsma JW, Lafeber FJ, Mastbergen SC. The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthritis Cartilage 2009, 17:482-488. 10.1016/j.joca.2008.09.002, 18926729.
79. Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Choquette D, Haraoui B, Abram F, Pelletier JP. An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin Arthritis Rheum 2010, 40:185-192. 10.1016/j.semarthrit.2009.10.003, 20132966.
80. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008, 58:3183-3191. 10.1002/art.23973, 2836125, 18821708.
81. Marks PH, Donaldson ML. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 2005, 21:1342-1347. 10.1016/j.arthro.2005.08.034, 16325085.
82. Ding C, Cicuttini F, Jones G. Do NSAIDs affect longitudinal changes in knee cartilage volume and knee cartilage defects in older adults?. Am J Med 2009, 122:836-842. 10.1016/j.amjmed.2009.03.022, 19699379.
83. Thwin MM, Douni E, Arjunan P, Kollias G, Kumar PV, Gopalakrishnakone P. Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice. Arthritis Res Ther 2009, 11:R138. 10.1186/ar2810, 2787297, 19765281.
84. Gebhard HH, Zysk SP, Schmitt-Sody M, Jansson V, Messmer K, Veihelmann A. The effects of Celecoxib on inflammation and synovial microcirculation in murine antigen-induced arthritis. Clin Exp Rheumatol 2005, 23:63-70.
85. El-Ghazaly MA, Nada AS, El-Hazek RM, Khayyal MT. Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats. Int J Radiat Biol 2010, 86:1079-1087. 10.3109/09553002.2010.501839, 20698743.
86. Bianchi M, Broggini M, Balzarini P, Franchi S, Sacerdote P. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract 2007, 61:1270-1277. 10.1111/j.1742-1241.2007.01453.x, 17590218.
87. Sutton S, Clutterbuck A, Harris P, Gent T, Freeman S, Foster N, Barrett-Jolley R, Mobasheri A. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J 2009, 179:10-24. 10.1016/j.tvjl.2007.08.013, 17911037.
88. Noguchi M, Kimoto A, Sasamata M, Miyata K. Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats. J Bone Miner Metab 2008, 26:461-468.
89. Taketa T, Sakai A, Tanaka S, Nakai K, Menuki K, Yamane H, Tanaka K, Nakamura T. Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells. J Bone Miner Metab 2008, 26:143-151. 10.1007/s00774-007-0808-2, 18301970.
90. Tsuboi H, Nampei A, Matsui Y, Hashimoto J, Kawai S, Ochi T, Yoshikawa H. Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis. Mod Rheumatol 2007, 17:115-122. 10.1007/s10165-007-0552-4, 17437166.